TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.

TRACON Pharmaceuticals Price Performance

Shares of TRACON Pharmaceuticals stock opened at $0.07 on Friday. The stock has a market cap of $250,635.00, a price-to-earnings ratio of 0.02 and a beta of 1.36. The firm’s 50-day moving average is $0.11 and its two-hundred day moving average is $1.20. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The firm had revenue of $0.06 million for the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.